130 related articles for article (PubMed ID: 16818684)
1. Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage.
Kote-Jarai Z; Matthews L; Osorio A; Shanley S; Giddings I; Moreews F; Locke I; Evans DG; Eccles D; ; Williams RD; Girolami M; Campbell C; Eeles R
Clin Cancer Res; 2006 Jul; 12(13):3896-901. PubMed ID: 16818684
[TBL] [Abstract][Full Text] [Related]
2. Determination of molecular markers for BRCA1 and BRCA2 heterozygosity using gene expression profiling.
Salmon AY; Salmon-Divon M; Zahavi T; Barash Y; Levy-Drummer RS; Jacob-Hirsch J; Peretz T
Cancer Prev Res (Phila); 2013 Feb; 6(2):82-90. PubMed ID: 23341570
[TBL] [Abstract][Full Text] [Related]
3. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients.
Walker LC; Thompson BA; Waddell N; ; Grimmond SM; Spurdle AB
PLoS Genet; 2010 Feb; 6(2):e1000850. PubMed ID: 20174566
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 missense variants of high and low clinical significance influence lymphoblastoid cell line post-irradiation gene expression.
Waddell N; Ten Haaf A; Marsh A; Johnson J; Walker LC; ; Gongora M; Brown M; Grover P; Girolami M; Grimmond S; Chenevix-Trench G; Spurdle AB
PLoS Genet; 2008 May; 4(5):e1000080. PubMed ID: 18497862
[TBL] [Abstract][Full Text] [Related]
5. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
Larsen MJ; Kruse TA; Tan Q; Lænkholm AV; Bak M; Lykkesfeldt AE; Sørensen KP; Hansen TV; Ejlertsen B; Gerdes AM; Thomassen M
PLoS One; 2013; 8(5):e64268. PubMed ID: 23704984
[TBL] [Abstract][Full Text] [Related]
6. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
7. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
8. Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2.
Buchholz TA; Wu X; Hussain A; Tucker SL; Mills GB; Haffty B; Bergh S; Story M; Geara FB; Brock WA
Int J Cancer; 2002 Feb; 97(5):557-61. PubMed ID: 11807777
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status.
Kote-Jarai Z; Williams RD; Cattini N; Copeland M; Giddings I; Wooster R; tePoele RH; Workman P; Gusterson B; Peacock J; Gui G; Campbell C; Eeles R
Clin Cancer Res; 2004 Feb; 10(3):958-63. PubMed ID: 14871973
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers.
Jazaeri AA; Yee CJ; Sotiriou C; Brantley KR; Boyd J; Liu ET
J Natl Cancer Inst; 2002 Jul; 94(13):990-1000. PubMed ID: 12096084
[TBL] [Abstract][Full Text] [Related]
11. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
12. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.
Antoniou AC; Beesley J; McGuffog L; Sinilnikova OM; Healey S; Neuhausen SL; Ding YC; Rebbeck TR; Weitzel JN; Lynch HT; Isaacs C; Ganz PA; Tomlinson G; Olopade OI; Couch FJ; Wang X; Lindor NM; Pankratz VS; Radice P; Manoukian S; Peissel B; Zaffaroni D; Barile M; Viel A; Allavena A; Dall'Olio V; Peterlongo P; Szabo CI; Zikan M; Claes K; Poppe B; Foretova L; Mai PL; Greene MH; Rennert G; Lejbkowicz F; Glendon G; Ozcelik H; Andrulis IL; ; Thomassen M; Gerdes AM; Sunde L; Cruger D; Birk Jensen U; Caligo M; Friedman E; Kaufman B; Laitman Y; Milgrom R; Dubrovsky M; Cohen S; Borg A; Jernström H; Lindblom A; Rantala J; Stenmark-Askmalm M; Melin B; ; Nathanson K; Domchek S; Jakubowska A; Lubinski J; Huzarski T; Osorio A; Lasa A; Durán M; Tejada MI; Godino J; Benitez J; Hamann U; Kriege M; Hoogerbrugge N; van der Luijt RB; van Asperen CJ; Devilee P; Meijers-Heijboer EJ; Blok MJ; Aalfs CM; Hogervorst F; Rookus M; ; Cook M; Oliver C; Frost D; Conroy D; Evans DG; Lalloo F; Pichert G; Davidson R; Cole T; Cook J; Paterson J; Hodgson S; Morrison PJ; Porteous ME; Walker L; Kennedy MJ; Dorkins H; Peock S; ; Godwin AK; Stoppa-Lyonnet D; de Pauw A; Mazoyer S; Bonadona V; Lasset C; Dreyfus H; Leroux D; Hardouin A; Berthet P; Faivre L; ; Loustalot C; Noguchi T; Sobol H; Rouleau E; Nogues C; Frénay M; Vénat-Bouvet L; ; Hopper JL; Daly MB; Terry MB; John EM; Buys SS; Yassin Y; Miron A; Goldgar D; ; Singer CF; Dressler AC; Gschwantler-Kaulich D; Pfeiler G; Hansen TV; Jønson L; Agnarsson BA; Kirchhoff T; Offit K; Devlin V; Dutra-Clarke A; Piedmonte M; Rodriguez GC; Wakeley K; Boggess JF; Basil J; Schwartz PE; Blank SV; Toland AE; Montagna M; Casella C; Imyanitov E; Tihomirova L; Blanco I; Lazaro C; Ramus SJ; Sucheston L; Karlan BY; Gross J; Schmutzler R; Wappenschmidt B; Engel C; Meindl A; Lochmann M; Arnold N; Heidemann S; Varon-Mateeva R; Niederacher D; Sutter C; Deissler H; Gadzicki D; Preisler-Adams S; Kast K; Schönbuchner I; Caldes T; de la Hoya M; Aittomäki K; Nevanlinna H; Simard J; Spurdle AB; Holland H; Chen X; ; Platte R; Chenevix-Trench G; Easton DF;
Cancer Res; 2010 Dec; 70(23):9742-54. PubMed ID: 21118973
[TBL] [Abstract][Full Text] [Related]
13. Gene-expression profiles in hereditary breast cancer.
Hedenfalk I; Duggan D; Chen Y; Radmacher M; Bittner M; Simon R; Meltzer P; Gusterson B; Esteller M; Kallioniemi OP; Wilfond B; Borg A; Trent J; Raffeld M; Yakhini Z; Ben-Dor A; Dougherty E; Kononen J; Bubendorf L; Fehrle W; Pittaluga S; Gruvberger S; Loman N; Johannsson O; Olsson H; Sauter G
N Engl J Med; 2001 Feb; 344(8):539-48. PubMed ID: 11207349
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility.
Barwell J; Pangon L; Georgiou A; Kesterton I; Langman C; Arden-Jones A; Bancroft E; Salmon A; Locke I; Kote-Jarai Z; Morris JR; Solomon E; Berg J; Docherty Z; Camplejohn R; Eeles R; Hodgson SV
Int J Cancer; 2007 Oct; 121(7):1631-6. PubMed ID: 17582599
[TBL] [Abstract][Full Text] [Related]
15. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
[TBL] [Abstract][Full Text] [Related]
16. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
[TBL] [Abstract][Full Text] [Related]
19. Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.
; ;
Breast Cancer Res Treat; 2008 May; 109(1):67-75. PubMed ID: 17972172
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
